Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 24
2018 66
2019 99
2020 98
2021 93
2022 68
2023 50
2024 51
2025 44
2026 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

540 results

Results by year

Filters applied: . Clear all
Page 1
Glecaprevir/Pibrentasvir: First Global Approval.
Lamb YN. Lamb YN. Drugs. 2017 Oct;77(16):1797-1804. doi: 10.1007/s40265-017-0817-y. Drugs. 2017. PMID: 28929412 Review.
A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET (EU); MAVYRET (USA)] has been developed by AbbVie. ...This article summarizes the m …
A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibr …
Public health round-up.
[No authors listed] [No authors listed] Bull World Health Organ. 2019 Jan 1;97(1):4-5. doi: 10.2471/BLT.19.010119. Bull World Health Organ. 2019. PMID: 30618458 Free PMC article. No abstract available.
Characterizing complex and competing drug-drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine.
Kosloski MP, Li H, Wang S, Mensa F, Kort J, Liu W. Kosloski MP, et al. Clin Transl Sci. 2023 Apr;16(4):593-605. doi: 10.1111/cts.13471. Epub 2023 Jan 23. Clin Transl Sci. 2023. PMID: 36597378 Free PMC article.
The fixed-dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once-daily treatment for all six major genotypes of chronic hepatitis C virus infection. ...
The fixed-dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once-daily tre …
The use of antiviral drugs in children.
Motisi MA, Tamborino A, Parigi S, Galli L, de Martino M, Chiappini E. Motisi MA, et al. J Chemother. 2022 Apr;34(2):73-86. doi: 10.1080/1120009X.2021.1979746. Epub 2021 Oct 11. J Chemother. 2022. PMID: 34633268
However, in some cases, the disease can be severe and lead to permanent disabilities. A variety of antiviral drugs are available for the treatments of certain infectious agents: for instance, acyclovir is used to treat herpes simplex virus encephalitis. ...However, …
However, in some cases, the disease can be severe and lead to permanent disabilities. A variety of antiviral drugs are available for …
Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta-Analysis.
Le DHH, Nguyen DC, Kanokudom S, Puenpa J, Nilyanimit P, Tran AN, Honsawek S, Poovorawan Y. Le DHH, et al. Rev Med Virol. 2025 Nov;35(6):e70074. doi: 10.1002/rmv.70074. Rev Med Virol. 2025. PMID: 41127976
This systematic review and meta-analysis compared the efficacy and safety of two pan-genotypic direct-acting antiviral regimens, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), for treating chronic HCV GT6. ...
This systematic review and meta-analysis compared the efficacy and safety of two pan-genotypic direct-acting antiviral regimens, glec …
Glecaprevir + pibrentasvir for treatment of hepatitis C.
Carrion AF, Martin P. Carrion AF, et al. Expert Opin Pharmacother. 2018 Mar;19(4):413-419. doi: 10.1080/14656566.2018.1444030. Epub 2018 Mar 7. Expert Opin Pharmacother. 2018. PMID: 29465262 Review.
Expert opinion: Glecaprevir/pibrentasvir is the latest antiviral regimen licensed in the United States for treatment of HCV infection. Although several other direct-acting antiviral agents (DAAs) are currently available, glecaprevir/pibrentasvir …
Expert opinion: Glecaprevir/pibrentasvir is the latest antiviral regimen licensed in the United States for treatment of HCV in …
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.
Kim AY, Kang M, Umbleja T, Nunes EP, Marks KM, Luetkemeyer AF, Koebele C, Wimbish C, Fierer DS, Kliemann DA, Solomon SS, Kort J, Kiser JJ, Lauer GM, Chung RT, Sowah LA, Alston-Smith BL, Wyles DL, Naggie S; A5380 Study Team. Kim AY, et al. Clin Infect Dis. 2026 Feb 4;81(6):1083-1090. doi: 10.1093/cid/ciaf305. Clin Infect Dis. 2026. PMID: 40736252 Free PMC article.
METHODS: PURGE-C (A5380) was a single-arm, multicenter trial evaluating the treatment of early HCV (primary or reinfection) with 4 weeks of glecaprevir/pibrentasvir (G/P). Early HCV was defined as new detectable HCV RNA or alanine aminotransferase (ALT) elevation within 24 …
METHODS: PURGE-C (A5380) was a single-arm, multicenter trial evaluating the treatment of early HCV (primary or reinfection) with 4 weeks of …
A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
Llibre JM, Boesecke C, Moon J, Lank PM, Miller MG, Fredrick LM, Welhaven A, Semizarov D, Marcinak J, Gentile I, Reiberger T, Puoti M. Llibre JM, et al. J Hepatol. 2026 Apr;84(4):702-712. doi: 10.1016/j.jhep.2025.11.009. Epub 2025 Nov 24. J Hepatol. 2026. PMID: 41297677 Free article. Clinical Trial.
This single-arm, phase IIIb study evaluated the efficacy and safety of an 8-week glecaprevir/pibrentasvir regimen in treatment-naive adults with acute HCV. METHODS: Analyzed populations included intention-to-treat (ITT; all patients receiving 1 glecaprevir/pibrentasvir …
This single-arm, phase IIIb study evaluated the efficacy and safety of an 8-week glecaprevir/pibrentasvir regimen in treatment-naive …
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
Cotter TG, Jensen DM. Cotter TG, et al. Drug Des Devel Ther. 2019 Jul 29;13:2565-2577. doi: 10.2147/DDDT.S172512. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31534310 Free PMC article. Review.
Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibit …
Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to th …
540 results